UNSPSC 51263121: Epanolol

This classification denotes a beta-adrenergic blocking agent with the molecular formula C20H23N3O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 9KGC55KP6A, chemically known as benzeneacetamide, n-(2-((3-(2-cyanophenoxy)-2-hydroxypropyl)amino)ethyl)-4-hydroxy- but generally known as epanolol, which bears US NIH Compound Identifier 72014. European Medicines Agency schedules Epanolol in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06558MIG.

UNSPSC 51263121 Epanolol, a Commodity code, does not map cleanly to the state and local opportunities recently tagged under it. The code nominally identifies a specific pharmaceutical compound; however, the recent solicitations reflect procurement of naloxone (an opioid antagonist unrelated to epanolol), safe drug deactivation systems, and preliminary market research into direct-to-manufacturer prescription programs. Neither opportunity directly involves epanolol acquisition or related products. State and local governments soliciting under this code appear to be pursuing emergency medical supplies and pharmacy benefit management solutions, but the mismatch between the code's pharmaceutical specificity and the actual work being bought suggests either tagging error or an artifact of how jurisdictions classify pharmaceutical procurements in their internal taxonomy systems.

The two most recent opportunities illustrate the disconnect. Seminole County, Florida posted IFB 60459723LAS in June 2026 seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually on a competitive-bid basis, with quarterly deliveries to the county community health building and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission issued an RFI in April 2026 (HHS0017013) to gather vendor capabilities for a Therapeutic Pharmacy Initiative direct-to-manufacturer prescription program—an exploratory procurement phase designed to inform future formal RFP strategy around pharmacy benefit contracting with self-insured employers and state agencies outside traditional pharmacy benefit manager arrangements. Neither solicitation names epanolol as a product line. The code shows minimal relevant recent activity for firms targeting authentic epanolol supply or related pharmaceutical commodities at the state or local level.